Efficacy and safety analysis of Dupilumab for atopic dermatitis of all ages in Chinese population: Real‐world data from a single center

AllergyEarly View LETTER Efficacy and safety analysis of Dupilumab for atopic dermatitis of all ages in Chinese population: Real-world data from a single center Zijing Yang, Zijing Yang orcid.org/0000-0002-7935-8018 Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorWanting Wen, Wanting Wen Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorRuofei Shi, Ruofei Shi Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorLihong Chen, Lihong Chen Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorHailun Wang, Hailun Wang Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorJie Zheng, Jie Zheng orcid.org/0000-0002-7961-6427 Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorHaiqin Zhu, Haiqin Zhu Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorMeng Pan, Meng Pan Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorXiaoqing Zhao, Corresponding Author Xiaoqing Zhao [email protected] orcid.org/0000-0002-9232-1412 Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China Correspondence Xiaoqing Zhao, Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin Second Road, Shanghai 200025, China. Email: [email protected]Search for more papers by this author Zijing Yang, Zijing Yang orcid.org/0000-0002-7935-8018 Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorWanting Wen, Wanting Wen Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorRuofei Shi, Ruofei Shi Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorLihong Chen, Lihong Chen Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorHailun Wang, Hailun Wang Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorJie Zheng, Jie Zheng orcid.org/0000-0002-7961-6427 Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorHaiqin Zhu, Haiqin Zhu Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorMeng Pan, Meng Pan Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorXiaoqing Zhao, Corresponding Author Xiaoqing Zhao [email protected] orcid.org/0000-0002-9232-1412 Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China Correspondence Xiaoqing Zhao, Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin Second Road, Shanghai 200025, China. Email: [email protected]Search for more papers by this author First published: 29 February 2024 https://doi.org/10.1111/all.16078 Xiaoqing Zhao and Meng Pan are co-corresponding authors to this work. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Open Research DATA AVAILABILITY STATEMENT The data that supports the findings of this study are available in the supplementary material of this article. Supporting Information Filename Description all16078-sup-0001-TablesS1-S4.docxWord 2007 document , 43.3 KB Tables S1–S4. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Pagan AD, David E, Ungar B, Ghalili S, He H, Guttman-Yassky E. Dupilumab improves clinical scores in children and adolescents with moderate to severe atopic dermatitis: a real-world, single-center study. J Allergy Clin Immunol Pract. 2022; 10(9): 2378-2385. 10.1016/j.jaip.2022.06.014 PubMedWeb of Science®Google Scholar 2Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019; 81(1): 143-151. 10.1016/j.jaad.2019.02.053 CASPubMedWeb of Science®Google Scholar 3Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021; 84(1): 139-147. 10.1016/j.jaad.2020.08.051 CASPubMedWeb of Science®Google Scholar 4Gu C, Wu Y, Luo Y, et al. Real-world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single-centre, prospective, open-label study. J Eur Acad Dermatol Venereol. 2022; 36(7): 1064-1073. 10.1111/jdv.18109 CASPubMedWeb of Science®Google Scholar 5Sharma M, Suratannon N, Leung D, et al. Human germline gain-of-function in STAT6: from severe allergic disease to lymphoma and beyond. Trends Immunol. 2024; 45(2): 138-153. 10.1016/j.it.2023.12.003 PubMedGoogle Scholar 6Owji S, Ungar B, Dubin DP, et al. No association between dupilumab use and short-term cancer development in atopic dermatitis patients. J Allergy Clin Immunol Pract. 2022; 11(5): 1548-1551. 10.1016/j.jaip.2022.12.018 PubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation